顶尖ADC公司：成为全球肿瘤学领导者

DAIICHI SANKYO HiroyukiOkuzawaPresident and CEO January 12, 2026 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses inthis material are all classified as Daiichi Sankyo’s future prospects. These forward-looking statements were determined by Daiichi Sankyobased on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risksas well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo’soutlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will berealized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the dutytoupdate the contentof this material from the date of this material onward. Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agencyworldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. Thereare no guarantee that these compounds will become commercially available in indications under investigation. Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absoluteaccuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any informationregarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this materialhas beencompiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of theaccuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof. The information described in this material may be changed hereafter without notice. Accordingly, this material or the information describedherein should be used at your own judgment, together with any other information you may otherwise obtain. This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere. Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitationdamages related to the use of erroneous information. Agenda Overview of Daiichi Sankyo1 Our ADCs2 Our Science and Technology3 Shareholder Returns4 Closing5 Overview of Daiichi Sankyo Overview of FY2025 consolidated P&L (Bn JPY) *As an indicator of ordinary profitability, “core operating profit” which excludes temporary income and expenses from operatingincome is disclosed.Income and expenses related to sale of fixed assets, restructuring (excluding the sales of pipeline and launched products),impairment, loss compensation, reconciliation,and other non-temporary and material gains and losses are included in the “temporary income and expenses”.Temporary income and expenses are excluded from results and forecast for cost of sales, SG&A expenses and R&D expenses shown in the list above. Agenda Overview of Daiichi Sankyo1 Our ADCs2 Our Science and Technology3 Shareholder Returns4 Closing DXdADC isDaiichi Sankyo OriginalADCTechnologyPlatform Our ADC technology platform is growing, and we have generated 7DXd ADCs from the technology External Evaluation ofDXdADCTechnology Since 2017, a total of 14Breakthrough Therapy designations*have beengrantedin the United States I-DXd Daiichi Sankyo Won Three World ADC Awards in 2025 Daiichi Sankyo’s DXd ADCTechnologyrecognized for“Best ADC Platform Technology” TROP2 Directed ADCrecognized for“Best ADC Clinical Impact” HER2 Directed ADCrecognized for“Best ADC Clinical Publication” Daiichi Sankyo has delivered by maximizing ENHERTU®since our launch inFY2019 and created the most successful launch in oncology over the last 5 years 1573.4 Bn JPY cumulative global net sales since 1st launch DESTINY-Breast09: Launch of ENHERTU®in 1stLine HER2+mBCwill be anear-term growth catalyst with potential to benefit 24k eligible patients Market Opportunity(Eligible patient numbers) DESTINY-Breast09Clinicaltrial data: PFS (BICR) •Currently, ~30% of patientsdo not receive treatmentbeyond first line. ~24,000*Market opportunity in G7 *Incremental to 2L Eligible patients: ~7,000 External Excitement for 1L HER2+mBC “This is a pivotal advancement for thetreatment of HER2-positive metastaticbreast cancer” STAT Statistically significant and clinicallymeaningful PFS benefit with T-DXd+ P(median Δ 13.8mo) The strong results in delaying progression“make it a clear front-runner” as an initialtreatment for HER2 patients Bloomberg